Recent Developments to Cope the Antibacterial Resistance via β-Lactamase Inhibition

Recent Developments to Cope the Antibacterial Resistance via β-Lactamase Inhibition

Antibacterial resistance towards the β-lactam (BL) drugs is now ubiquitous, and there is a major global health concern associated with the emergence of new β-lactamases (BLAs) as the primary cause of resistance. In addition to the development of new antibacterial drugs, β-lactamase inhibition is an...

Full description

Bibliographic Details
Main Authors:	Zafar Iqbal, Jian Sun, Haikang Yang, Jingwen Ji, Lili He, Lijuan Zhai, Jinbo Ji, Pengjuan Zhou, Dong Tang, Yangxiu Mu, Lin Wang, Zhixiang Yang
Format:	Article
Language:	English
Published:	MDPI AG 2022-06-01
Series:	Molecules
Subjects:	antibacterial resistance β-lactamase inhibitor diazabicyclooctane boronic acids avibactam relebactam
Online Access:	https://www.mdpi.com/1420-3049/27/12/3832

Similar Items

β-Lactamase inhibition profile of new amidine-substituted diazabicyclooctanes
by: Zafar Iqbal, et al.
Published: (2021-03-01)

The Effectiveness of Imipenem–Relebactam against Ceftazidime-Avibactam Resistant Variants of the KPC-2 β-Lactamase
by: Krisztina M. Papp-Wallace, et al.
Published: (2023-05-01)

Synergistic Effect of Clinically Available Beta-Lactamase Inhibitors Combined with Cefiderocol against Carbapenemase-Producing Gram-Negative Organisms
by: Gabriele Bianco, et al.
Published: (2022-11-01)

Aztreonam Combinations with Avibactam, Relebactam, and Vaborbactam as Treatment for New Delhi Metallo-β-Lactamase-Producing Enterobacterales Infections—In Vitro Susceptibility Testing
by: Małgorzata Brauncajs, et al.
Published: (2024-03-01)

Pharmacokinetics of Non-β-Lactam β-Lactamase Inhibitors
by: Giacomo Luci, et al.
Published: (2021-06-01)

Structural Comparisons of Cefotaximase (CTX-M-ase) Sub Family 1
by: Ben A. Shurina, et al.
Published: (2021-08-01)

New Antibiotics for the Treatment of Nosocomial Central Nervous System Infections
by: Roland Nau, et al.
Published: (2024-01-01)

Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients
by: François Barbier, et al.
Published: (2023-07-01)

The Role of Colistin in the Era of New β-Lactam/β-Lactamase Inhibitor Combinations
by: Abdullah Tarık Aslan, et al.
Published: (2022-02-01)

Comparison of In Vitro Activity of Ceftazidime-Avibactam and Imipenem-Relebactam against Clinical Isolates of Pseudomonas aeruginosa
by: Leilei Wang, et al.
Published: (2023-06-01)

In vitro activity of ceftazidime-avibactam, imipenem-relebactam, aztreonam-avibactam, and comparators toward carbapenem-resistant and hypervirulent Klebsiella pneumoniae isolates
by: Dan Li, et al.
Published: (2023-12-01)

Allergic Reactions and Cross-Reactivity Potential with Beta-Lactamase Inhibitors
by: Kayla R. Stover, et al.
Published: (2019-06-01)

Comparison of the inoculum effect of in vitro antibacterial activity of Imipenem/relebactam and Ceftazidime/avibactam against ESBL-, KPC- and AmpC-producing Escherichia coli and Klebsiella pneumoniae
by: Xueting Wang, et al.
Published: (2023-12-01)

A New Twist: The Combination of Sulbactam/Avibactam Enhances Sulbactam Activity against Carbapenem-Resistant <i>Acinetobacter baumannii</i> (CRAB) Isolates
by: Fernando Pasteran, et al.
Published: (2021-05-01)

Review of In Vitro Efficacy of Ceftazidime-Avibactam, Meropenem-Vaborbactam and Imipenem-Relebactam in Carbapenemase Producing Klebsiella pneumoniae Isolates
by: Özlem AYDEMİR, et al.
Published: (2023-09-01)

Treatment of UTIs Due to <i>Klebsiella pneumoniae</i> Carbapenemase-Producers: How to Use New Antibiotic Drugs? A Narrative Review
by: Caroline Chapelle, et al.
Published: (2021-11-01)

Treatment and diagnosis of severe KPC-producing Klebsiella pneumoniae infections: a perspective on what has changed over last decades
by: Daniele Roberto Giacobbe, et al.
Published: (2023-12-01)

Drug Regimens of Novel Antibiotics in Critically Ill Patients with Varying Renal Functions: A Rapid Review
by: Julie Gorham, et al.
Published: (2022-04-01)

Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections
by: Helio S. Sader, et al.
Published: (2021-12-01)

In Vitro Activity of Auranofin in Combination With Aztreonam-Avibactam Against Metallo-β-lactamase (MBL)-Producing Enterobacterales
by: Wen Wang, et al.
Published: (2021-10-01)

Comparative Activities of Novel Therapeutic Agents against Molecularly Characterized Clinical Carbapenem-Resistant Enterobacterales Isolates
by: Jocelyn Qi-Min Teo, et al.
Published: (2023-06-01)

Efficacy and safety of novel carbapenem-β-lactamase inhibitor combinations: imipenem-cilastatin/relebactam results from randomized controlled trials
by: Qingxin Yang, et al.
Published: (2023-12-01)

What to Do with the New Antibiotics?
by: Khalil Chaïbi, et al.
Published: (2023-03-01)

Therapeutic Options for Metallo-β-Lactamase-Producing Enterobacterales
by: Tan X, et al.
Published: (2021-01-01)

Identification of Mutations in the <italic toggle="yes">mrdA</italic> Gene Encoding PBP2 That Reduce Carbapenem and Diazabicyclooctane Susceptibility of <named-content content-type="genus-species">Escherichia coli</named-content> Clinical Isolates with Mutations in <italic toggle="yes">ftsI</italic> (PBP3) and Which Carry <italic toggle="yes">bla</italic><sub>NDM-1</sub>
by: Srijan Ranjitkar, et al.
Published: (2019-08-01)

Activity of imipenem/relebactam on Klebsiella pneumoniae with different mechanisms of imipenem non-susceptibility
by: Mervat Mashaly, et al.
Published: (2022-02-01)

Activity of imipenem/relebactam on Klebsiella pneumoniae with different mechanisms of imipenem non-susceptibility
by: Mervat Mashaly, et al.
Published: (2022-06-01)

Activity of imipenem/relebactam on Klebsiella pneumoniae with different mechanisms of imipenem non-susceptibility
by: Mervat El-Sayed Mashaly, et al.
Published: (2021-12-01)

Interactions between Avibactam and Ceftazidime-Hydrolyzing Class D β-Lactamases
by: Jean-Marie Frère, et al.
Published: (2020-03-01)

In Vitro Antibacterial Activity of Imipenem/Relebactam against Clinical Isolates in Japan
by: Dai Kurihara, et al.
Published: (2022-04-01)

<i>Klebsiella pneumoniae</i> Susceptibility to Carbapenem/Relebactam Combinations: Influence of Inoculum Density and Carbapenem-to-Inhibitor Concentration Ratio
by: Maria V. Golikova, et al.
Published: (2022-06-01)

Cefmetazole Resistance Mechanism for Escherichia Coli Including ESBL-Producing Strains
by: Ito R, et al.
Published: (2022-10-01)

In vitro activity of aztreonam–avibactam against metallo-β-lactamase-producing Enterobacteriaceae—A multicenter study in China
by: Biying Zhang, et al.
Published: (2020-08-01)

<italic toggle="yes">Klebsiella pneumoniae</italic> Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from β-Lactamase Protein Engineering
by: Melissa D. Barnes, et al.
Published: (2017-11-01)

Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Enterobacterales Analyzed by ICU and Non-ICU Wards, Infection Sources, and Geographic Regions: ATLAS Program 2016–2020
by: Denis Piérard, et al.
Published: (2023-11-01)

A Simple Disk Stacking Plus Micro-Elution Method for Rapid Detection of the Synergistic Effect of Aztreonam and Ceftazidime/Avibactam Against Metallo-β-Lactamase Producing Enterobacterales
by: Liu Z, et al.
Published: (2023-03-01)

The <i>Klebsiella pneumoniae</i> carbapenemase (KPC) β-Lactamase Has Evolved in Response to Ceftazidime Avibactam
by: Sona Garsevanyan, et al.
Published: (2023-12-01)

A practical laboratory method to determine ceftazidime-avibactam-aztreonam synergy in patients with New Delhi metallo-beta-lactamase (NDM)–producing Enterobacterales infection
by: Timothy Miles Rawson, et al.
Published: (2022-06-01)

In-Vitro Selection of Ceftazidime/Avibactam Resistance in OXA-48-Like-Expressing <i>Klebsiella pneumoniae</i>: In-Vitro and In-Vivo Fitness, Genetic Basis and Activities of β-Lactam Plus Novel β-Lactamase Inhibitor or β-Lactam Enhancer Combinations
by: Snehal Palwe, et al.
Published: (2021-10-01)

Increased zinc levels facilitate phenotypic detection of ceftazidime-avibactam resistance in metallo-β-lactamase-producing Gram-negative bacteria
by: Michaela Simon, et al.
Published: (2022-11-01)